Products & Services · Revenues:

Tukysa — Revenues:

Pfizer Tukysa — Revenues: increased by 2.5% to $122.00M in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 19.6%, from $102.00M to $122.00M.

Analysis

StatementSegment
First reportedQ1 2021
Last reportedQ1 2026May 5, 2026
Rolls up toTotal Revenue
Metric ID: pfe_segment_tukysa_revenues

Historical Data

20 periods
 Q2 '21Q3 '21Q4 '21Q1 '22Q2 '22Q3 '22Q4 '22Q1 '23Q2 '23Q3 '23Q4 '23Q1 '24Q2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26
Value$0.00$0.00$0.00$0.00$0.00$0.00$0.00$0.00$0.00$0.00$18.00M$106.00M$121.00M$124.00M$129.00M$102.00M$132.00M$110.00M$119.00M$122.00M
QoQ Change+488.9%+14.2%+2.5%+4.0%-20.9%+29.4%-16.7%+8.2%+2.5%
YoY Change+616.7%-3.8%+9.1%-11.3%-7.8%+19.6%
Range$0.00$132.00M
Avg YoY Growth+103.8%
Median YoY Growth+2.7%
Current Streak2 quarters growth

Frequently Asked Questions

What is Pfizer's tukysa — revenues:?
Pfizer (PFE) reported tukysa — revenues: of $122.00M in Q1 2026.
How has Pfizer's tukysa — revenues: changed year-over-year?
Pfizer's tukysa — revenues: increased by 19.6% year-over-year, from $102.00M to $122.00M.